Second-Line Treatment of Advanced Pancreatic Cancer with Oxaliplatin, Fluorouracil and Leucovorin (OFF Regimen)

A clinical practice guideline for patients with advanced or metastatic pancreatic cancer. The guideline examines the use of oxaliplatin, fluorouracil and leucovorin in patients who had received, or were intolerant to, gemcitabine-based therapy. Outcomes of interest include progression-free and overall survival.